Sun Pharmaceutical Industries Ltd.

SECTOR: Pharmaceuticals & Drugs

455.2
₹ 18.55 (4.25%)
Today's High: 473.85 Today's Low : 443.6
52 Week High: 479.60 52 Week Low : 315.20
 FinStar
FinStar Indicates the overall health and quality of a stock based on Finology Research.
Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.

 Company Essentials

Market Cap

109217.7278344 Cr.

P/E

34.97

P/B

4.54

Face Value

₹1

Div. Yield

0.57%

Book Value (TTM)

100.2832

Enterprise Value

115313.5978344 Cr.

CASH

340.77 Cr.

DEBT

6436.64 Cr.

Promoter Holding

54.56%

EPS (TTM)

13.0176

Sales Growth

14.70 %

ROE

3.62 %

ROCE

4.31 %

Profit Growth

167.18 %

No. of Shares

239.933497 Cr.

Add your own Ratio
* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

 Price Chart 1w1m3m6m1Yr3Yr5Yr

* Prices are based on daily market changes.

 Valuation Chart 1w1m3m6m1Yr3Yr5Yr

* The chart is based on the standalone earnings of the company.

 Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Sales Growth

1 Year14.7%
3 Year10.04%
5 Year29.5%

 Profit Growth

1 Year167.21%
3 Year40.12%
5 Year18.01%

 ROE

1 Year3.62%
3 Year1.64%
5 Year-1.95%

 ROCE

1 Year4.31%
3 Year2.48%
5 Year0.11%

 Debt Equity

0.28

 Price to Cash Flow

87.92

  Interest Cover Ratio

2.33

 CFO/PAT

13.9675693546393

 Share Holding Pattern

 Promoter Pledging %

Date Promoter % Pledge %
Dec 2019 54.56 10.07
Sep 2019 54.55 10.41
Jun 2019 54.38 10.97
Mar 2019 54.38 10.97
Dec 2018 54.38 7.54
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 40.1171901705706% for the Past 3 years.
  • Company’s PEG ratio is 0.209164034361188.
  • The company has a good cash flow management; CFO/PAT stands at 1.52116091109478.

 Limitations

  • The company has shown a poor revenue growth of 10.0362439125823% for the Past 3 years.
  • Company has a poor ROE of 1.64% over the past 3 years.
  • Company has a poor ROCE of 2.48% over the past 3 years
  • Tax rate is low at -13.5.
  • The company has a low EBITDA margin of 1.402% over the past 5 years.
  • The company is trading at a high PE of 140.81.
  • The company is trading at a high EV/EBITDA of 39.99.

 Quarterly Result (All Figures are in Crores.)

Particulars Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019
Net Sales 2261.26 2552.13 3309.01 3373.29 3013.55
Other Income 69.83 679.23 40.67 258.33 61.79
Total Expenditure 2128.72 1993.63 2388.71 2538.38 2354.17
Operating Profit 202.37 1237.73 960.97 1093.24 721.17
Interest 133.38 119.37 57.25 114.47 98.76
Depreciation 134.06 132.18 135.58 139.14 144.4
Exceptional Items 0 0 0 0 0
Profit Before Tax -65.07 986.18 768.14 839.63 478.01
Tax -26.39 -81.88 4.77 16.47 9.25
Profit After Tax -38.68 1068.06 763.37 823.16 468.76

 Profit & Loss (All Figures are in Crores except Adjusted EPS in Rs.)

Particulars Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
Net Sales 8028.4 7733.3 7684 8982.5 10303.2
Other Income 317.8 445.1 689.7 1251.6 1286.2
Total Expenditure 8693.3 8151.9 7744.6 8127.8 8561.7
Operating Profit -347 26.4 629.1 2106.3 3027.7
Interest 551.3 574.1 223.6 388.3 540.9
Depreciation 660.7 464.3 422.3 487.2 553
Exceptional Items 0 -70.1 0 -950.5 -1214.4
Profit Before Tax -1559 -1082.1 -16.8 280.3 719.5
Tax -84.8 5.5 6 -25.4 -97.2
Net Profit -1474.1 -1087.5 -22.8 305.6 816.6
Adjusted EPS -7 -5 0 1 3

 Balance Sheet (All Figures are in Crores.)

Particulars Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
Equity and Liabilities
Share Capital 207.12 240.66 239.93 239.93 239.93
Total Reserves 22579.15 21650.04 20772.54 22082.68 22603.68
Borrowings 1170.32 1922.84 760.64 1564.69 1422.5
Other N/C liabilities 3526.33 2163.37 1473.9 683.99 514.09
Current liabilities 11052.08 8627.3 10962.65 12558.42 13271.83
Total Liabilities 38535 34604.21 34209.66 37129.71 38052.03
Assets
Net Block 3185.27 3574.62 4038.63 4644.57 4978.42
Capital WIP 1086.32 765.4 1055.11 830.39 456.25
Investments 25782.23 22298.13 19293.29 18310.5 17656.16
Loans & Advances 2978.67 2497.9 3325.06 3600.73 3592.57
Other N/C Assets 52.23 151.9 109.38 168.31 198.86
Current Assets 5450.28 5316.26 6388.19 9575.21 11169.77
Total Assets 38535 34604.21 34209.66 37129.71 38052.03
* Other Non-current Liabilities include Net deferred Liabilities

 Cash Flows (All Figures are in Crores.)

Particulars Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
Profit Before Tax -1558.97 -1082.06 -16.8 280.25 719.45
Adjustment 585.98 765.34 -51.25 -294.77 448.66
Working Capital Changes 1315.06 -585.04 -769.35 -865.29 111.5
Tax Paid -193.48 -352.73 -783.6 -291.42 -37.43
Operating Cash Flow 148.59 -1254.49 -1621 -1171.23 1242.18
Investing Cash Flow 2152.81 3639.2 2381.38 1391.62 433.69
Financing Cash Flow -2674.09 -2368.03 -752.99 -272.1 -1468.59
Net Cash Flow -372.69 16.68 7.39 -51.71 207.28

 Corporate Actions

 Ratings & Research Reports

 Company Presentations

 Sun Pharma Inds. Stock Price Analysis and Quick Research Report

Is Sun Pharma Inds. an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Sun Pharma Inds. and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 1242.18 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Sun Pharma Inds. has a Debt to Equity ratio of 0.28176982534722 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Sun Pharma Inds. , the EPS growth was 167.18 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Sun Pharma Inds. has OPM of 14.0413949239577 % which is a bad sign for profitability.
     
  • ROE: Sun Pharma Inds. have a poor ROE of 3.61597671888416 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
X